Business Description
Fulcrum Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US3596161097
Description
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 28.37 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.31 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 4.78 | |||||
| Beneish M-Score | 19.6 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -49.1 | |||||
| 3-Year EBITDA Growth Rate | 13.5 | |||||
| 3-Year EPS without NRI Growth Rate | 17.1 | |||||
| 3-Year FCF Growth Rate | 11.7 | |||||
| 3-Year Book Growth Rate | 3.7 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.23 | |||||
| 9-Day RSI | 33.05 | |||||
| 14-Day RSI | 33.61 | |||||
| 6-1 Month Momentum % | -49.93 | |||||
| 12-1 Month Momentum % | 6.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 22.07 | |||||
| Quick Ratio | 22.07 | |||||
| Cash Ratio | 21.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -30.4 | |||||
| Shareholder Yield % | 1.28 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -40.15 | |||||
| Net Margin % | -24.79 | |||||
| FCF Margin % | -15.46 | |||||
| ROE % | -8.07 | |||||
| ROA % | -7.42 | |||||
| ROIC % | -179.58 | |||||
| 3-Year ROIIC % | 526.04 | |||||
| ROC (Joel Greenblatt) % | -263.42 | |||||
| ROCE % | -12.63 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.56 | |||||
| PB Ratio | 0.74 | |||||
| Price-to-Tangible-Book | 0.73 | |||||
| EV-to-EBIT | 1.89 | |||||
| EV-to-Forward-EBIT | -1.25 | |||||
| EV-to-EBITDA | 2.01 | |||||
| EV-to-Forward-EBITDA | -1.27 | |||||
| EV-to-Revenue | -0.76 | |||||
| EV-to-Forward-Revenue | 3.67 | |||||
| EV-to-FCF | 4.91 | |||||
| Price-to-Net-Current-Asset-Value | 0.77 | |||||
| Price-to-Net-Cash | 0.79 | |||||
| Earnings Yield (Greenblatt) % | 52.91 | |||||
| FCF Yield % | -6.24 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FULC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fulcrum Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 81.63 | ||
| EPS (TTM) ($) | -0.35 | ||
| Beta | 2.76 | ||
| Volatility % | 113.06 | ||
| 14-Day RSI | 33.61 | ||
| 14-Day ATR ($) | 0.271954 | ||
| 20-Day SMA ($) | 3.44775 | ||
| 12-1 Month Momentum % | 6.57 | ||
| 52-Week Range ($) | 2.865 - 13.7 | ||
| Shares Outstanding (Mil) | 62.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fulcrum Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fulcrum Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Fulcrum Therapeutics Inc Frequently Asked Questions
What is Fulcrum Therapeutics Inc(FULC)'s stock price today?
The current price of FULC is $3.23. The 52 week high of FULC is $13.70 and 52 week low is $2.87.
When is next earnings date of Fulcrum Therapeutics Inc(FULC)?
The next earnings date of Fulcrum Therapeutics Inc(FULC) is .
Does Fulcrum Therapeutics Inc(FULC) pay dividends? If so, how much?
Fulcrum Therapeutics Inc(FULC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers